biosimilar semaglutide Biosimilars: Impact on Mainland China Chinese drugmakers seek to emulate

Its growing presence in research environments has made it a recognised option for those building advanced and multi-compound research protocols

Gut Microbes 7(3):189200 Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L et al (2016) Probiotics in prevention and treatment of obesity: a critical view

GLP-1 Agonists Show Promise in Treating Substance Use Disorders Nov 7, 2025 5 min read Updated: Dec 17, 2025 In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditionssuch as semaglutide and liraglutideare showing promise in treating substance use disorders (SUDs)

Researchers found that people taking GLP-1 drugs were 66% more likely to be diagnosed with gastroparesis than those who were not

How exciting is that

Ayala A, Munoz MF, Arguelles S